Leon A Epps

Title: **Leon A. Epps: Innovator in Peptide Therapeutics**

Introduction

Leon A. Epps is a notable inventor based in Baltimore, MD, with a significant contribution to the field of peptide therapeutics. With four patents to his name, his work focuses primarily on the development of peptide inhibitors that play a crucial role in mediating inflammation and leukocyte adhesion.

Latest Patents

Among his latest innovations, Epps has developed peptide inhibitors targeting inflammation mediated by selectins. These peptides, derived from the lectin domain of GMP-140 (also known as P-selectin) and related selectins, have shown efficacy in inhibiting neutrophil adhesion. The invention reveals that variations in the core sequence and flanking regions do not affect biological activity, making these peptides vital for diagnostic tools and potential clinical applications in managing coagulation and inflammation. Additionally, he has patented novel peptides derived from specific segments of the amino acid sequence of P-selectin, which also serve therapeutic and diagnostic purposes in pharmaceutical compositions.

Career Highlights

Epps has had a distinguished career working with notable organizations such as Centocor, Inc. and the University of Oklahoma. His tenure at these institutions underscores his dedication to advancing medical science through innovation.

Collaborations

Throughout his career, Epps has collaborated with esteemed colleagues, including George A. Heavner and Marian Kruszynski. These partnerships have contributed to the development of important scientific advancements in his field.

Conclusion

Leon A. Epps’s contributions through his patents highlight the impact of peptide-based therapies in addressing critical health issues related to inflammation and adhesion processes. His work not only emphasizes the importance of innovation in biotechnology but also points to a future where his discoveries may play a key role in therapeutic applications.